Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-28T00:31:12.091Z Has data issue: false hasContentIssue false
  • English
  • Français

Colonization With Methicillin-Resistant Staphylococcus aureus in ICU Patients Morbidity, Mortality, and Glycopeptide Use

Published online by Cambridge University Press:  02 January 2015

Maité Garrouste-Orgeas ,
Jean-Francois Timsit ,
Hatem Kallel ,
Adel Ben Ali ,
Marie Francoise Dumay ,
Benedicte Paoli ,
Benoit Misset  and
Jean Carlet
Maité Garrouste-Orgeas*
Affiliation:
Service de Réanimation Polyvalente, Hôpital Saint Joseph, Paris, France
Jean-Francois Timsit
Affiliation:
Service de Réanimation Polyvalente, Hôpital Saint Joseph, Paris, France Département de Biostatistiques et Informatique médicate, Hopital Saint Louis, Paris, France
Hatem Kallel
Affiliation:
Service de Réanimation Polyvalente, Hôpital Saint Joseph, Paris, France
Adel Ben Ali
Affiliation:
Service de Microbiologic Médicate, Hôpital Saint Joseph, Paris, France
Marie Francoise Dumay
Affiliation:
Service de Réanimation Polyvalente, Hôpital Saint Joseph, Paris, France
Benedicte Paoli
Affiliation:
Service de Réanimation Polyvalente, Hôpital Saint Joseph, Paris, France
Benoit Misset
Affiliation:
Service de Réanimation Polyvalente, Hôpital Saint Joseph, Paris, France
Jean Carlet
Affiliation:
Service de Réanimation Polyvalente, Hôpital Saint Joseph, Paris, France
*
Service de Réanimation Polyvalente, Fondation Hopital Saint Joseph, 185 Rue Raymond Losserand, 75014 Paris, France
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To determine the impact of methicillin-resis-tant Staphylococcus aureus (MRSA) colonization on the occurrence of S aureus infections (methicillin-resistant and methicillin-suscep-tible), the use of glycopeptides, and outcome among intensive care unit (ICU) patients.

Design:

Prospective observational cohort survey.

Setting:

A medical-surgical ICU with 10 single-bed rooms in a 460-bed, tertiary-care, university-affiliated hospital.

Patients:

A total of 1,044 ICU patients were followed for the detection of MRSA colonization from July 1, 1995, to July, 1 1998.

Methods:

MRSA colonization was detected using nasal samples in all patients plus wound samples in surgical patients within 48 hours of admission or within the first 48 hours of ICU stay and weekly thereafter. MRSA infections were defined using Centers for Disease Control and Prevention standard definitions, except for ventilator-associated pneumonia and catheter-related infections, which were defined by quantitative distal culture samples.

Results:

One thousand forty-four patients (70% medical patients) were included in the analysis. Mean age was 61±18 years; mean Simplified Acute Physiologic Score (SAPS) II was 36.4±20; and median ICU stay was 4 (range, 1-193) days. Two hundred thirty-one patients (22%) died in the ICU. Fifty-four patients (5.1%) were colonized with MRSA on admission, and 52 (4.9%) of 1,044 acquired MRSA colonization in the ICU. Thirty-five patients developed a total of 42 S aureus infections (32 MRSA, 10 methi-cillin-susceptible). After factors associated with the development of an S aureus infection were adjusted for in a multivariate Cox model (SAPS II >36: hazard ratio [HR], 1.64; P=.09; male gender: HR, 2.2; P=.05), MRSA colonization increased the risk of S aureus infection (HR, 3.84; P=.0003). MRSA colonization did not influence ICU mortality (HR, 1.01; P=.94). Glycopeptides were used in 11.4% of the patients (119/1,044) for a median duration of 5 days. For patients with no colonization, MRSA colonization on admission, and ICU-acquired MRSA colonization, respectively, glycopeptide use per 1,000 hospital days was 37.7, 235.2, and 118.3 days. MRSA colonization per se increased by 3.3-fold the use of glycopeptides in MRSA-colonized patients, even when an MRSA infection was not demonstrated, compared to non-colonized patients.

Conclusions:

In our unit, MRSA colonization greatly increased the risk of S aureus infection and of glycopeptide use in colonized and non-colonized patients, without influencing ICU mortality. MRSA colonization influenced glycopeptide use even if an MRSA infection was not demonstrated; thus, an MRSA control program is warranted to decrease vancomycin use and to limit glycopeptide resistance in gram-positive cocci.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 22 , Issue 11 , November 2001 , pp. 687 - 692
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Leclercq, R, Courvalin, P. Resistance to glycopeptide in Enterococci. Clin Infect Dis 1997;24:545–556.CrossRefGoogle ScholarPubMed
2.Mainardi, JL, Shlaes, DM, Goering, RV, Shlaes, JH, Acar, JF, Goldstein, FW. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 1995;171:1646–1650.CrossRefGoogle ScholarPubMed
3.Quincampoix, JC, Carbonne, A, Loyer, D, Kitzis, MD, Coutrot, A, Timsit, JF, et al.Follow up of a nosocomial outbreak of methicillin-resistant strains of Staphylococcus aureus (MRSA) with decreased susceptibility to teicoplanin (DST). Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 1997; Toronto, Ontario, Canada. Abstract C-167.Google Scholar
4.Smith, TL, Pearson, ML, Wilcox, KR, Cosme Cruz, PH, Lancaster, MV, Robinson-Dunn, B, et al.Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493–501.CrossRefGoogle ScholarPubMed
5.Sieradkzi, K, Roberts, RB, Haber, SW, Tomasz, A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517–523.Google Scholar
6.Vincent, JL, Bihari, DJ, Suter, PM, Bruining, HA, White, J, Nicolas-Chanoin, MH, et al.The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) study. EPIC International Advisory Committee. JAMA 1995;274:639–644.CrossRefGoogle Scholar
7.Le Gall, JR, Lemeshow, S, Saulnier, F. A new Simplified Acute Physiologic Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957–2963.CrossRefGoogle Scholar
8.Chastre, J, Fagon, JY, Bornet-Lesco, ML, Calvat, S, Dombret, MC, Al Khani, R, et al.Evaluation of bronchoscopic techniques for the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 1995;152:231–240.CrossRefGoogle ScholarPubMed
9.Timsit, JF, Misset, B, Goldstein, FW, Carlet, J. Reappraisal of distal diagnostic testings in the diagnosis of nosocomial pneumonia. Chest 1995;108:1632–1639.CrossRefGoogle Scholar
10.Brun-Buisson, C, Abroug, F, Legrand, P. Diagnosis of central venous catheter-related infection: critical level of quantitative tip cultures. Arch Intern Med 1987;47:873–877.CrossRefGoogle Scholar
11.Garner, JS, Jarvis, WR, Emori, TG, Horan, TC, Hughes, JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140.CrossRefGoogle ScholarPubMed
12.Société de Réanimation de Langue Française. Utilisation de l'indice de gravité simplifiée et du système oméga. Mise à jour 1986. Commission d'Evaluation de la Société de Langue Française. Réanimation Soins Intensifs Médecine Urgences 1986;2:219–221.Google Scholar
13.Stamm, AM, Long, MN, Belcher, B. Higher overall nosocomial infection rate because of increased attack rate of methicillin-resistant Staphylococcus aureus. Am J Infect Control 1993;21:70–74.CrossRefGoogle ScholarPubMed
14.Girou, E, Pujade, G, Legrand, P, Cizeau, F, Brun-Buisson, C. Selective screening of carriers for control of methicillin-resistant Staphylococcus aureus (MRSA) in high-risk hospital areas with a high level of endemic MRSA. Clin Infect Dis 1999;27:543–550.CrossRefGoogle Scholar
15.Pujol, M, Pena, C, Pallares, R, Ariza, J, Ayats, J, Dominguez, MA, et al.Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med 1996;100:509–516.CrossRefGoogle ScholarPubMed
16.Muder, RR, Brennen, C, Wagener, MM, Vickers, RM, Rihs, JD, Hancock, GA, et al.Methicillin-resistant staphylococcal colonization and infection in a long term care facility. Ann Intern Med 1991;114:107–112.CrossRefGoogle ScholarPubMed
17.Corbella, X, Dominguez, MA, Pujol, M, Ayats, J, Sendra, M, Pallares, R, et al.Staphylococcus aureus nasal carriage as a marker for subsequent staphylococcal infections in intensive care unit patients. Eur J Clin Microbiol Infect Dis 1997;16:351–357.CrossRefGoogle ScholarPubMed
18.von Eiff, C, Becker, K, Machka, K, Stammer, H, Peters, G. Nasal carriage as a source of Staphylococcus aureus bacteremia Study Group. N Engl J Med 2001;344:11–16.CrossRefGoogle ScholarPubMed
19.Fierobe, J, Deere, D, Muller, C, Lucet, JC, Marmuse, JP, Mantz, J, et al.Methicillin-resistant Staphylococcus aureus as a causative agent of postoperative intra-abdominal infection: relation to nasal colonization. Clin Infect Dis 1999;29:1231–1238.CrossRefGoogle ScholarPubMed
20.Bert, F, Galdbart, JO, Zarrouk, V, Le Mee, J, Durand, F, Mentre, F, et al.Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients. Clin Infect Dis 2000;31:1295–1298.CrossRefGoogle ScholarPubMed
21.Kalmeijer, MD, van Nieuwland-Bollen, E, Bogaers-Hofman, D, de Baere, GA.. Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infect Control Hosp Epidemiol 2000;21:319–323.CrossRefGoogle Scholar
22.Ruef, C, Fanconi, S, Nadal, D. Sternal wound infection after heart operations in pediatric patients associated with nasal carriage of Staphylococcus aureus. J Thorac Cardiovasc Surg 1996;112:681–686.CrossRefGoogle ScholarPubMed
23.Knaus, WA, Zimmerman, JE, Wagner, DP, Draper, EA, Lawrence, DE. APACHE—Acute Physiologic and Chronic Health Evaluation: a physiologically based classification system. Crit Care Med 1981;9:591–597.CrossRefGoogle ScholarPubMed
24.Bueno-Cavanillas, A, Delgado-Rodriguez, M, Lopez-Luque, A, Schaffino-Cano, S, Galvez-Vargas, R. Influence of nosocomial infection on mortality rate in an intensive care unit. Crit Care Med 1994;22:55–60.CrossRefGoogle Scholar
25.Reardon, CM, La, H, Brown, TP, Stephenson, AJ, Freedlander, E. Methicillin-resistant Staphylococcus aureus in burn patients. Why all the fuss ? Burns 1998;24:393–397.CrossRefGoogle ScholarPubMed
26.Fridkin, SK, Edwards, JR, Pichette, SC, Pryor, ER, McGowan, JE, Tenover, FC, et al.Determinants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin Infect Dis 1999;28:1119–1125.CrossRefGoogle ScholarPubMed
27.Hiramatsu, K, Hanaki, H, Ino, T, Yabuta, K, Oguri, T, Tenover, FC. Methicillin-resistant Staphylococcus aureus strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135–136.CrossRefGoogle ScholarPubMed
28.Bhorade, SM, Christenson, J, Pohlman, AS, Arnow, PM, Hall, JB. The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients. Crit Care Med 1999;115:1085–1091.Google ScholarPubMed
29.Hospital Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Preventing the spread of vancomycin resistance: a report from the Hospital Infection Control Practices Advisory Committee prepared by the Subcommittee on Prevention and Control of Antimicrobial-Resistant Micro-organisms in Hospitals. Infect Control Hosp Epidemiol 1995;16:105–113.Google Scholar
30.Evans, ME, Milheim, ET, Rapp, RP. Vancomycin use in a university medical center: effect of a vancomycin continuation form. Infect Control Hosp Epidemiol 1999;20:417–420.CrossRefGoogle Scholar
31.Lipsky, BA, Baker, CA, McDonald, LL, Suzuki, NT. Improving the appropriateness of vancomycin use by sequential interventions. Am J Infect Control 1999;27:84–90.CrossRefGoogle ScholarPubMed
32.Roghmann, MC, Perdue, BE, Polish, L. Vancomycin use in a hospital with vancomycin restriction. Infect Control Hosp Epidemiol 1999;20:60–63.CrossRefGoogle Scholar
33.Hamilton, CD, Drew, R, Janning, SW, Latour, JK, Hayward, S. Excessive use of vancomycin: a successful intervention strategy at an academic medical center. Infect Control Hosp Epidemiol 2000;21:42–45.CrossRefGoogle ScholarPubMed
34.Monnet, DL. Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Infect Control Hosp Epidemiol 1998;19:552–559.CrossRefGoogle ScholarPubMed
35.Boyce, JM. Should we vigorously try to contain and control methicillin-resistant Staphylococcus aureus? Infect Control Hosp Epidemiol 1991;12:46–54.CrossRefGoogle ScholarPubMed
36.Chaix, C, Durand-Zaleski, I, Alberti, C, Brun-Buisson, C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999;282:1745–1751.CrossRefGoogle Scholar
37.Asencio, A, Guerrero, A, Querada, C, Lizan, M, Martinez-Ferrer, M. Colonization and infection with methicillin-resistant Staphylococcus aureus: associated risk factors and eradication. Infect Control Hosp Epidemiol 1996;17:20–28.CrossRefGoogle Scholar
38.Grundmann, H. Methicillin-Resistant Staphylococcus aureus in a Teaching Hospital: Investigation of Nosocomial Transmission Using a Matched Case-Control Study. Dissertation. London, England: London School of Hygiene and Tropical Medicine; 1997.Google Scholar